AstraZeneca to present survival data at ESMO 2026
By United One News · AI-generated summary of 7 outlets' reporting
Published · Updated
AI-generated summary of the coverage listed below:
AstraZeneca announced plans to present overall survival data from four pivotal phase three trials during presidential symposia at the European Society for Medical Oncology Congress in October 2026.
- The upcoming presentations will feature data for Sone─Ve, Imfinzi, Tagrisso, and Orpathys.
- The company aims to showcase new findings from its diverse oncology portfolio and pipeline.
- The medical congress is scheduled to take place from October 23 to 27.
Covered by 7 outlets across the spectrum: 0% left, 71% center, 14% right.
How each side framed it
AstraZeneca to present overall survival data from four pivotal phase III trials in Presidential Symposia at ESMO 2026 featuring Sone─Ve, Imfinzi, Tagrisso & Orpathys
AstraZeneca’s Experimental Stomach Cancer Drug Doubles Survival in Late-Stage Trial
Timeline
First to report: Pharmabiz (); 7 articles from 7 outlets so far.
Who is covering this story
- Center (5): Pharmabiz, Globenewswire_fr, Investing Uk, Investing Australia, PR Newswire Asia
- Right-leaning (1): Times Now
- Not yet rated (1): Stat
Sources
- AstraZeneca to present overall survival data from four pivotal phase III trials in Presidential Symposia at ESMO 2026 featuring Sone─Ve, Imfinzi, Tagrisso & Orpathys — Pharmabiz (center, AI-estimated) ·
- Enterome Phase 1/2 data show OncoMimics™ EO4010-induced CD8 T-cell expansion was associated with longer survival in patients with colorectal cancer — Globenewswire_fr (center, AI-estimated) ·
- Amgen at ESMO: IMDELLTRA data points to earlier lung cancer use — Investing Uk (center, AI-estimated) ·
- Amgen at ESMO: IMDELLTRA data points to earlier lung cancer use — Investing Australia (center, AI-estimated) ·
- Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting — PR Newswire Asia (center, AI-estimated) ·
- STAT+: At ESMO, AstraZeneca’s cancer pursuits get a showcase — Stat (not yet rated, AI-estimated) ·
- AstraZeneca’s Experimental Stomach Cancer Drug Doubles Survival in Late-Stage Trial — Times Now (right-leaning) ·